Douglas Carr Biography and Net Worth

Doug Carr is Principal Financial Officer at Century Therapeutics. Prior to joining Century, Doug was Vice President of Finance at Novira Therapeutics, where he directed all financial and fiscal management aspects of the company’s operations and participated in the execution of the sale of Novira to Johnson & Johnson. Previously, Doug was Financial Controller for Omthera Pharmaceuticals, where he established the finance and accounting infrastructure and led the company through an IPO and subsequent sale to Astra Zeneca in 2013. Additionally, he held various financial leadership positions at Merck, and started his career at PWC (formerly Cooper & Lybrand). Doug holds a BA from Rutgers University and is a Certified Public Accountant in the State of New Jersey. Doug currently serves on the Board of Directors at Heritage Conservancy in Doylestown, Pennsylvania.

What is Douglas Carr's net worth?: The estimated net worth of Douglas Carr is at least $1.12 million as of March 12th, 2026. Carr owns 507,261 shares of Century Therapeutics stock worth more than $1,115,974 as of April 28th. This net worth estimate does not reflect any other assets that Carr may own. Learn More about Douglas Carr's net worth.
How do I contact Douglas Carr?: The corporate mailing address for Carr and other Century Therapeutics executives is , , . Century Therapeutics can also be reached via phone at 267-817-5790 and via email at [email protected]. Learn More on Douglas Carr's contact information.
Has Douglas Carr been buying or selling shares of Century Therapeutics?: Douglas Carr has not been actively trading shares of Century Therapeutics during the past quarter. Most recently, Douglas Carr sold 7,043 shares of the business's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $2.55, for a transaction totalling $17,959.65. Following the completion of the sale, the senior vice president now directly owns 507,261 shares of the company's stock, valued at $1,293,515.55. Learn More on Douglas Carr's trading history.
Who are Century Therapeutics' active insiders?: Century Therapeutics' insider roster includes Douglas Carr (SVP), Eli Casdin (Director), Osvaldo Flores (Pres), Brent Pfeiffenberger (CEO), and Gregory Russotti (Insider). Learn More on Century Therapeutics' active insiders.
Are insiders buying or selling shares of Century Therapeutics?: During the last year, Century Therapeutics insiders bought shares 3 times. They purchased a total of 145,060 shares worth more than $97,011.00. During the last year, insiders at the sold shares 18 times. They sold a total of 92,974 shares worth more than $80,629.43. The most recent insider tranaction occured on March, 12th when SVP Douglas Carr sold 7,043 shares worth more than $17,959.65. Insiders at Century Therapeutics own 4.4% of the company. Learn More about insider trades at Century Therapeutics.
Information on this page was last updated on 3/12/2026.

Douglas Carr Insider Trading History at Century Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/12/2026	Sell	7,043	$2.55	$17,959.65	507,261
2/3/2026	Sell	323	$1.82	$587.86	514,551
12/8/2025	Sell	257	$0.53	$136.21	404,874
11/3/2025	Sell	292	$0.59	$172.28	405,131
9/8/2025	Sell	263	$0.50	$131.50	405,423
6/9/2025	Sell	4,904	$0.62	$3,040.48	405,982
5/5/2025	Sell	295	$0.55	$162.25	410,886
3/10/2025	Sell	1,240	$0.61	$756.40	315,556
2/3/2025	Sell	351	$0.78	$273.78	316,796
11/4/2024	Sell	283	$1.23	$348.09	317,147
8/5/2024	Sell	289	$1.83	$528.87	334,041
5/3/2024	Sell	257	$3.11	$799.27	317,323
2/5/2024	Sell	643	$3.84	$2,469.12	304,137

Douglas Carr Buying and Selling Activity at Century Therapeutics

Century Therapeutics Company Overview

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Today's Range

Now: $2.20

$2.16

$2.27

50 Day Range

MA: $2.31

$1.93

$2.94

2 Week Range

Now: $2.20

$0.44

$3.04

Volume

543,566 shs

Average Volume

1,703,245 shs

Market Capitalization

$396.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66